What is Illuccix?
Illuccix (gallium Ga 68 gozetotide) is an FDA-approved radioactive diagnostic agent for positron emission tomography (PET) imaging. It targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to detect metastases or recurrence in patients with suspected prostate cancer.[1]
How is Illuccix used?
Doctors inject Illuccix intravenously before a PET/CT scan. It binds to PSMA-positive lesions, lighting them up for imaging. The FDA approved it in 2021 for:
- Patients with prostate cancer recurrence based on elevated PSA levels.
- Initial staging of high-risk prostate cancer before treatment.[1][2]
Imaging occurs 50-100 minutes post-injection, with results read within hours.
Who makes Illuccix and when was it approved?
Telix Pharmaceuticals manufactures Illuccix. The FDA granted approval on December 20, 2021, under a New Drug Application (NDA). It's available in single-dose vials (148-296 MBq/mL).[1][3]
What are common side effects?
Most patients experience no serious issues. Reported reactions include injection site pain (0.4%), headache, nausea, or fatigue (<1%). Allergic reactions are rare but possible—monitor for rash or breathing issues. Radiation exposure is low, comparable to other PET scans.[1][2]
How much does Illuccix cost?
A single dose averages $4,000-$5,000 in the US, often covered by Medicare for eligible patients. Prices vary by provider and insurance; cash-pay options exist through manufacturer assistance programs.[4]
When does Illuccix patent protection end?
Illuccix holds patents covering the gozetotide compound and kit formulation. Key US patents expire between 2033 and 2037, with potential extensions. No generics are approved yet—check DrugPatentWatch.com for litigation updates and Paragraph IV challenges.[5]
How does Illuccix compare to other PSMA PET agents?
| Agent | Manufacturer | Key Difference | Approval Year |
|-------|--------------|----------------|---------------|
| Illuccix (68Ga-gozetotide) | Telix | Widely available; room-temp stable up to 4 hours | 2021 |
| Pylarify (18F-DCFPyL) | Lantheus | Longer half-life (110 min vs 68 min); higher resolution | 2021 |
| Posluma (18F-flotufolastat) | Blue Earth | No cyclotron needed nearby; shelf-stable 6 hours | 2023 |
| Locametz (68Ga-PSMA-11) | Novartis | First approved; shorter stability | 2020 |
Illuccix excels in supply chain ease due to centralized production.[2][3]
Who qualifies for Illuccix scans?
Men with:
- PSA recurrence post-treatment (biochemical failure).
- High- or very high-risk prostate cancer for staging.
Not for initial screening or non-PSMA-expressing tumors. Confirm PSMA expression if prior therapy.[1]
What do patients report after Illuccix scans?
Scans often clarify ambiguous cases, guiding decisions on radiation, surgery, or hormone therapy. Some note mild arm soreness from injection; scans take 30 minutes. Patient forums highlight faster staging vs bone scans, reducing overtreatment.[6]
[1]: FDA.gov - Illuccix Label (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215791s000lbl.pdf)
[2]: TelixPharma.com - Illuccix (https://illuccix.com/)
[3]: ASCO Post - PSMA PET Approvals (https://ascopost.com/news/december-2021/fda-approves-illuccix-for-prostate-cancer-imaging/)
[4]: GoodRx - Illuccix Pricing (https://www.goodrx.com/illuccix)
[5]: DrugPatentWatch.com - Illuccix Patents (https://www.drugpatentwatch.com/p/tradename/ILLUCCIX)
[6]: ProstateCancerFoundation.org - Patient Stories (https://www.pcf.org/patient-resources/psma-pet-imaging/)